Since the COVID-19 pandemic began, various screening tests for the virus have become available. Our insured members are reimbursed according to the following conditions:
|Test name||SARS-COV-2 detection||Conditions||Reimbursement|
Mucous membrane swab.
Detection and diagnosis of the virus in case of symptoms or suspicion.
Must be carried out by a healthcare professional at an official testing centre or a doctor’s surgery in strict compliance with the requirements pertaining to suspicion, sampling and declaration.
These analyses must be carried out on the basis of a medical prescription and the results must be delivered by a doctor duly licensed to practise in the country in which he or she operates.
|Reimbursed by the CHIS/UNIQA upon presentation of a medical prescription|
Identification of the presence of IgM and IgG antibodies specific to SARS-COV-2.
Determines an individual’s immune status at the time of blood sample, i.e. whether he or she has developed antibodies to the virus.
Serological analyses must be carried out exclusively by analysis laboratories that are authorised to perform them, in accordance with the laws governing epidemics and the associated implementing orders.
These tests are not relevant for the diagnosis of virus infection.
|Not reimbursed by the CHIS/UNIQA|
available over the counter in pharmacies or online, without medical prescription
|Self-test performed by dripping droplets of blood onto testing strips.||These tests are not medically recognised: the results are unreliable as false positives and negatives occur frequently.||Not reimbursed by the CHIS/UNIQA|